Meropenem: an updated review of its use in the management of intra-abdominal infections (Q34059386)

30 July 2017

1 reference

title

Meropenem: an updated review of its use in the management of intra-abdominal infections (English)

1 reference

30 July 2017

1 reference

M N Lowe

1 reference

30 July 2017

H M Lamb

series ordinal

1 reference

30 July 2017

language of work or name

1 reference

1 September 2000

1 reference

30 July 2017

1 reference

30 July 2017

1 reference

30 July 2017

1 reference

30 July 2017

page(s)

619-646

1 reference

30 July 2017

1 reference

12 December 2020

Carbapenems in clinical practice: a guide to their use in serious infection

1 reference

12 December 2020

The pharmacokinetics of meropenem in surgical patients with moderate or severe infections

1 reference

12 December 2020

Antimicrobial susceptibility of viridans group streptococci

1 reference

12 December 2020

Effect of pH on in vitro antimicrobial susceptibility of the Bacteroides fragilis group

1 reference

12 December 2020

Prospective, randomised, multicentre study of meropenem versus imipenem/cilastatin as empiric monotherapy in severe nosocomial infections

1 reference

12 December 2020

Effect of meropenem on the intestinal microflora

1 reference

12 December 2020

Safety profile of meropenem: a review of nearly 5,000 patients treated with meropenem

1 reference

12 December 2020

Meropenem versus imipenem/cilastatin as empirical monotherapy for serious bacterial infections in the intensive care unit

1 reference

12 December 2020

Impact an anatomical site on bacteriological and clinical outcome in the management of intra-abdominal infections.

1 reference

12 December 2020

Cost-effectiveness study of imipenem/cilastatin versus meropenem in intra-abdominal infections

1 reference

12 December 2020

A review of the in vitro activity of meropenem and comparative antimicrobial agents tested against 30,254 aerobic and anaerobic pathogens isolated world wide

1 reference

12 December 2020

In vitro activities of aminomethyl-substituted analogs of novel tetrahydrofuranyl carbapenems

1 reference

12 December 2020

Effect of altered volume of distribution on aminoglycoside levels in patients in surgical intensive care

1 reference

12 December 2020

Pharmacokinetic monitoring of nephrotoxic antibiotics in surgical intensive care patients

1 reference

12 December 2020

A randomized, double-blind clinical trial comparing cefepime plus metronidazole with imipenem-cilastatin in the treatment of complicated intra-abdominal infections. Cefepime Intra-abdominal Infection Study Group.

1 reference

12 December 2020

Pharmacokinetics of meropenem in patients with liver disease

1 reference

12 December 2020

Bactericidal activity, post antibiotic effect and modified controlled effective regrowth time of meropenem at high concentrations

1 reference

12 December 2020

Meropenem versus tobramycin with clindamycin in the antibiotic management of patients with advanced appendicitis.

1 reference

12 December 2020

Imipenem/cilastatin (1.5 g daily) versus Meropenem (3.0 g daily) in Patients with Intra-abdominal Infections: Results of a Prospective, Randomized, Multicentre Trial

1 reference

12 December 2020

Results of a randomized, multicenter trial of meropenem versus clindamycin/tobramycin for the treatment of intra-abdominal infections

1 reference

12 December 2020

1 reference

12 December 2020

Management of intra-abdominal infections. The case for intraoperative cultures and comprehensive broad-spectrum antibiotic coverage. The Canadian Intra-abdominal Infection Study Group

1 reference

12 December 2020

In vitro activity of cefepime against multidrug-resistant Gram-negative bacilli, viridans group streptococci and Streptococcus pneumoniae from a cross-Canada surveillance study

1 reference

12 December 2020

[Meropenem (Merrem) vs imipenem/cilastatin in hospital treatment of intra-abdominal infections. A multicenter study].

1 reference

12 December 2020

In vitro activities of nontraditional antimicrobials against multiresistant Acinetobacter baumannii strains isolated in an intensive care unit outbreak

1 reference

12 December 2020

Emergence of antibiotic-resistant bacteria in cases of peritonitis after intraabdominal surgery affects the efficacy of empirical antimicrobial therapy

1 reference

12 December 2020

Pharmacoeconomics of meropenem versus imipenem/cilastatin

1 reference

12 December 2020

Meropenem versus cefuroxime plus gentamicin for treatment of serious infections in elderly patients

1 reference

12 December 2020

Secondary bacterial peritonitis: The biologic basis of treatment

1 reference

12 December 2020

Antibiotic trials in intra-abdominal infections. A critical evaluation of study design and outcome reporting.

1 reference

12 December 2020

In-vitro studies of meropenem

1 reference

12 December 2020

Imipenem/cilastatin: an update of its antibacterial activity, pharmacokinetics and therapeutic efficacy in the treatment of serious infections

1 reference

12 December 2020

Meropenem versus imipenem/cilastatin in the treatment of intraabdominal infections requiring surgery

1 reference

12 December 2020

Carbapenem-induced resistance to beta-lactams in Pseudomonas aeruginosa.

1 reference

12 December 2020

Meropenem versus tobramycin plus clindamycin for treatment of intraabdominal infections: results of a prospective, randomized, double-blind clinical trial

1 reference

12 December 2020

In-vitro selection of porin-deficient mutants of two strains of Klebsiella pneumoniae with reduced susceptibilities to meropenem, but not to imipenem

1 reference

12 December 2020

In vitro activities of the potent, broad-spectrum carbapenem MK-0826 (L-749,345) against broad-spectrum beta-lactamase-and extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli clinical isolates

1 reference

12 December 2020

Rational antibiotic therapy for intra-abdominal infections

1 reference

12 December 2020

Meropenem in elderly and renally impaired patients

1 reference

12 December 2020

Pharmacodynamic effects of meropenem on gram-negative bacteria.

1 reference

12 December 2020

A multi-centre study to compare meropenem and cefotaxime and metronidazole in the treatment of hospitalized patients with serious infections.

1 reference

12 December 2020

Multicenter study of in vitro susceptibility of the Bacteroides fragilis group, 1995 to 1996, with comparison of resistance trends from 1990 to 1996

1 reference

12 December 2020

Meropenem versus imipenem/cilastatin in intra-abdominal infections requiring surgery. Meropenem Study Group.

1 reference

12 December 2020

Antimicrobial resistance amongst Klebsiella spp. collected from intensive care units in Southern and Western Europe in 1997-1998.

1 reference

12 December 2020

Pharmacokinetics of meropenem and its metabolite in young and elderly healthy men

1 reference

12 December 2020

Efficacy and safety of imipenem/cilastatin: a review of worldwide clinical experience.

1 reference

12 December 2020

Markedly different rates and resistance profiles exhibited by seven commonly used and newer beta-lactams on the selection of resistant variants of Enterobacter cloacae

1 reference

12 December 2020

Comparative in vitro activity of meropenem versus other routinely used antimicrobials against 18632 aerobic bacteria tested in 92 German centers

1 reference

12 December 2020

Postantibiotic Effect of Carbapenems against Pseudomonas aeruginosa

1 reference

12 December 2020

Meropenem: a review of its use in patients in intensive care

1 reference

12 December 2020

Comparative in vitro activity of meropenem versus other extended-spectrum antimicrobials against randomly chosen and selected resistant clinical isolates tested in 26 North American centers

1 reference

12 December 2020

The disposition and metabolic fate of 14C-meropenem in man.

1 reference

12 December 2020

Carbapenem-hydrolyzing beta-lactamases

1 reference

12 December 2020

Management of complicated intra-abdominal infections

1 reference

12 December 2020

The pharmacokinetics of meropenem

1 reference

12 December 2020

Postantibiotic effects of three carbapenems on Pseudomonas aeruginosa in the presence of lysine

1 reference

12 December 2020

Meropenem (1.5 g/day) is as effective as imipenem/cilastatin (2 g/day) for the treatment of moderately severe intra-abdominal infections.

1 reference

12 December 2020

Meropenem. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy

1 reference

12 December 2020

Meropenem. A pharmacoeconomic review of its use in serious infections

1 reference

12 December 2020

Acquired carbapenemases

1 reference

12 December 2020

Results of a randomized trial comparing sequential intravenous/oral treatment with ciprofloxacin plus metronidazole to imipenem/cilastatin for intra-abdominal infections. The Intra-Abdominal Infection Study Group

1 reference

12 December 2020

Antibiotic monotherapy with meropenem in the surgical management of intra-abdominal infections

1 reference

12 December 2020

Meropenem Clinical Pharmacokinetics

1 reference

12 December 2020

Safety profile of meropenem: international clinical experience based on the first 3125 patients treated with meropenem.

1 reference

12 December 2020

Intravenous meropenem versus imipenem/cilastatin in the treatment of serious bacterial infections in hospitalized patients. Meropenem Serious Infection Study Group

1 reference

12 December 2020

Mechanisms of resistance to the carbapenems.

1 reference

12 December 2020

Intraperitoneal penetration of meropenem

1 reference

12 December 2020

Meropenem versus imipenem/cilastatin in the treatment of intra-abdominal infections.

1 reference

12 December 2020

Evaluation of new anti-infective drugs for the treatment of intraabdominal infections. Infectious Diseases Society of America and the Food and Drug Administration

1 reference

12 December 2020

Antimicrobial susceptibility and frequency of occurrence of clinical blood isolates in Europe from the SENTRY antimicrobial surveillance program, 1997 and 1998

1 reference

12 December 2020

A compilation of meropenem tissue distribution data

1 reference

12 December 2020

Safety and efficacy of meropenem in hospitalised children: randomised comparison with cefotaxime, alone and combined with metronidazole or amikacin. Meropenem Paediatric Study Group

1 reference

12 December 2020

A proposed classification of intra-abdominal infections. Stratification of etiology and risk for future therapeutic trials

1 reference

12 December 2020

In vitro activities of Y-688, a new 7-substituted fluoroquinolone, against anaerobic bacteria.

1 reference

12 December 2020

Worldwide emergence of carbapenem-resistant Acinetobacter spp

1 reference

12 December 2020

Meropenem: clinical response in relation to in vitro susceptibility

1 reference

12 December 2020

Meropenem monotherapy versus cefotaxime plus metronidazole combination treatment for serious intra-abdominal infections.

1 reference

12 December 2020

Survey of bloodstream infections due to gram-negative bacilli: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, and Latin America for the SENTRY Antimicrobial Surveillance Program, 1997

1 reference

12 December 2020

Guidelines for clinical care: anti-infective agents for intra-abdominal infection. A Surgical Infection Society policy statement

1 reference

12 December 2020

In vitro activity of BMS-181139, a new carbapenem with potent antipseudomonal activity

1 reference

12 December 2020

[In vitro activity of carbapenems (biapenem, imipenem and meropenem) and some other antibiotics against strict anaerobic bacteria]

1 reference

12 December 2020

Meropenem pharmacokinetics and penetration into an inflammatory exudate

1 reference

12 December 2020

Trends in Antimicrobial Resistance of the Bacteroides fragilis Group: A 20‐Year Study at a Medical Center in Buenos Aires, Argentina

1 reference

12 December 2020

Results of a multicenter trial comparing imipenem/cilastatin to tobramycin/clindamycin for intra-abdominal infections

1 reference

12 December 2020

Meropenem: in-vitro activity and kinetics of activity against organisms of the Bacteroides fragilis group

1 reference

12 December 2020

Pharmacokinetics of meropenem in patients with intra-abdominal infections

1 reference

12 December 2020

A study of the penetration of meropenem into bile using endoscopic retrograde cholangiography

1 reference

12 December 2020

10.2165/00003495-200060030-00010

Identifiers

DOI

1 reference

Dimensions Publication ID

30 July 2017

1017580348

0 references

1 reference